(2) 8 – 1385 134-129 : !"# $% & !'(') *!'+ $&,"- .&% / 01 )2% %(" / '3 4 454 +% 6 !( 78 3M.D. 2M.D. 3 M.D. 2 M.D. * 1 Ph.D. 3M.Sc. !" . %)'% * %)F *'"G"6 .F9"< 3"3 ($) * .A,:0-&E= *(D@) ...% /"3 :6(= >4?@ AB0% * :/9 : ; < 85/10/19 :/53 549O >H@% I' 85/9/18 :A,6 LH% /53 MN' I' 85/6/28 :4& >H@% I' /H8 & ! " # $% : & /! ,0 1 23 !& . ' ' ()* +, * - * "! " , * 0 40 5# " 6 #, 7 8/9 : 0 ; <* =, ,>0 $&* $ "0 $ ! - 0 ?@ ; & < 7 A#* "0 .< # B C * $ A#* 0 #*0, (L) ... B $ 75 "0 D E& 0 * $ 0 1F G H : ?( ( 0 $ 40! T $ U0 +% .(0 ' , 25) R - 1384 4 $ 3 WA$ . " ' "/* " Visual Analysis Score (VAS) ?V G 7 ) $ R0 0 ' 0 R ' / 10 0 A#* 4#A* 40 0 ' : <#B& 0 ' $ D E& 1F Z 1 0 R ' / 10 0 $ 4#A* R$ 0 ' 0 0 R ' / 25 0 #*0, Downloaded from militarymedj.ir at 7:48 +0330 on Monday September 27th 2021 " , \- " C% "0 Z % =, 0 0 " / % W% . * [ E . (p< 0/05) * % " +, * Z W% 0 ' $ , VAS 0 :$ #*0, 0 ' 18 .(?' G0 (G ^ ( :0 \- " C% "0 Z % G0 ( 6 . 'G7 ` V $ 0 ' 6 0 A#* 0 ' 14 " " +, * 0 , (p>0/05) "0 # \ B& ;a& A#* # B #*0, bD c^d 5 e +, * <9 / $ * G ^ (p< 0/05) * - VAS 0 .( " * ;a& 5e "0 0 (# (p<0/05) !& 0 G H A#* 0 #*0, 6 ?@ ; !& :@* "0 $ $ c #*0, '* [ E 0 ' * " ? ! . +, * " 6 ;a& A#* bD . #*0, A#* $ $)G$ :.& 9;A( 6(75 . &45 3 .12 / 0 * + ,- .&'() ($) ... ! -1 e-mail: [email protected] : (; ($) ... 9 3 ($) ... -2 3 .12 / 0 * + ,- .&'() = * -3 %:G- & )F6 ,"Q 130 /,3 0 ' #D : " ,0 ;a& sE " # " 6 ' " ! 5/ f H2 0 H1 # ' 7 (F A#* 6 AG0 1d? & * ($ ($% EE@ !& .[21 20] !0 1 : 6 ' ()* +, * - [1] ' ' ZgGD 5 e F !0 0 ?* 0E & 5 Z =, .[2-4] 0 D d "t^d .[5] ($ $% " , - " H 0 0 <# u@? D 3 ' 6! G0 [6] ($ 6 & " , c& \ & : F& " ,0 U ` @ sE & $ )G$ .[7] ? 7 - i & 4 #*0, $ "0 $ ?@ ; & < 7 G H & )G0 % " 6G/$ dG7 5 Z .< # B #& A#* 0 0 [8] k' ;a& @ $ j 0 >)G ($% (D " 6G/$ ^ /! . 0 ^ - i $ 7& & %4 ' 0 0 0 < & $ )G$ * [10 9] R & 7 R0 B C * $ 0 G 7 * 1F G H V ' .[11] 5 <B # Z#*& ; (/ \ & 13844 $ 43 (L) ... B $ ! `#m ' "* 6& 6& ' 6 7 (^0 - "B $ * 75 & .($ R - * H - & *n * 3 , G0 v$ % : o/ @ " 6 0 He 4 . $% " , * . G H 0 (w (6! 0 o/ @ " 6 0 * & " , $ s $% Z #$ " 6 " 6 5 \ & * D ' e + 7 : 0 D ' e " 0 (m& k' * & * ,0 /! .[12] ^ 0 d +D " 6?*0 V G H 43 * =, D ' e ) $ * , ' ^ 0 : 1F . ' x G H 0 ($ #^ D0 &7 ! 5G * ,>0 $&* C?$ % /$0 G H +% 1 E@? [ E #' 3 0 ; <* ' =, 0 ($% 48 w*^ [22] 0 (; , ?$ % .[13] o) 17 . ' $ m 5^ "/* - <# " # * !& Downloaded from militarymedj.ir at 7:48 +0330 on Monday September 27th 2021 D ' c 33 "2 0 y$ 17-32 & ;p [14 6] ($ #, " ,& " $7 +% VAS (Visual Analysis Score) =, . 7 D ' * 7 " * & * 6 .[23] " ' " /* G H U0 #*0, ,0 <e 5# . #, , #, 0 ' Z : <#B& 0 ' $ D E& 3 " 6/&0 % * <, 0 !& +% 6G $ s e R0 0 ' 0 25 mg0 #*0, s e (/ q[15] F& $ "0 A#* 4#A* R$ 0 ' 0 0 10mg 0 $ C $ 6? 1 ; 0 "j – $ &* % W% . * [ E Z 1 0 10mg 0 rH$ +, * 0 'G7 ` -' ) "* E 0 0 D ' e 0 0 .[17 16] ($ 0m 6 7 #' -& (" , , , . $ m \- 6 7 VAS $ c H1 (# ' 7 " , #, 7 R0 5# . e , ?$ % Z 43 - ) $ * - " * ! * " , $ % W% Z =, "07` 0 0 Z [ E ,0 . ' e . D ' e \- [18] "j – $ R 0 <e 5# (# * bd " * 8E& 1384 4 $ G H 0 D 3 .[19] " ? k% G H U0 .(D ' e (L) ... B % R/ C? 2 85 131 … !"# $% & !'(') *!'+ $&,"- .&% / 01 )2% %(" / '3 : $ 0 p<0/001 : #*0, p<0/001:A#*) . G ^ "/* G H " 5 * r:& : .(1-40!) (p<0/001 7 z " + 7 " ,0 * ^ bD 0 ' $ W% 1 "# B 1F & $ 7 =, . (D ( : 8& & . 0 ' $ " 7 [d !0 . C T & LG Z % 0 ' , 0 * A#* '* [ E 1 y$ * 0 SPSS13 " 7 D R "/$0 1 d3 "/* ( 6 C ? $ '*[ E 0 C G 7 Chi-square 0 ANOVA " ,7 ) $ a& VAS $ Z* bD [d !0 .(p=0/019) .(D ' e " 7 .(p=0/043) ' ` 5 &B y$& ' ! D' 0 ' 6 A#* 0 ' 14 (sedation) 'G7 [ E 0 Z 1 75 & +,0{% .(p = 0/238) #*0, 0 ' 18 0 $ (D 0 ' 4 $ 42/3 ±5/4 $ y$ . * . (p = 0/974) , ? 0 ' , 2 -' * [ E 0 ' 44/3± 6/3 A#* * & 6& " C% "0 " 6 #*0, '* [ E 0 ' 4 $ 41/1 ± 6/2 0 $ w* 0 * 6 * . G H , .(p =0/756) U0 B " \ B& (?' V \- "0 U0 5e y$ " C% " 0 W% y$ . 8& & #*0, 0 $ A#* " 6,0 ' 0 ' 31/81±7/32 A#* 0 ' .(p=0/666) 34/59±3/42 0 33/56±4/60 33/67±4/45 $ 0 ' 0 33/14±7/21 #*0, G H U0 6,0 ' VAS B C [d U0 (# * 32/76±7/14 69/23±18/36 0 64/36±16/39 68/90±17/32 8& & "0 " 6 VAS .(1 40!) ( " y$ 0 8& (D Z 1 W% .(p=0/560) Z U0 " ' B " C% A#* * [ E 0 ' $ 0 ' 61/60±17/33 $ 0 ' * "3 24/48±4/06 8& & #*0, 0 $ #*0, 0 ' 0 62/59±19/11 A#* y$ . (1 ) $ 25/86 ± 3/12 0 27/64±3/89 +% (# 6 7 [d * $ 63/36±22/68 0 46/08±18/82 32/10±14/67 8& & VAS .(1 40!) (# " 7 } mG +, * , ? * (D +, * 40/64±20/94 Downloaded from militarymedj.ir at 7:48 +0330 on Monday September 27th 2021 0 $ , "* (D VAS 0 .o/ @ " , 1 [ m 0 C :1 6(&C /!') < /) $'/( ± (/)! '(/! ± $/%& $$/# ± !/ /#' < /) $)/%) ± (/$' '!/!% ± !/ $$/( ± !/!# +* ,- ./ /$)( < /) $$/)! ± (/') '#/% ± $/)' $!/#& ± $/!' 0*1 /%'# /)& / p value < /'%( < /) )/ ± )(/$$ !/% ± )%/%' !/$ ± )/$& < /)$ < /) '/&# ± )&/)) $'/) ± )!/( %/& ± )(/$' +* VAS /)% < /) $/$ ± ''/% !/! ± '/&! &/'$ ± )%/$ 0*1 /&!& /!$ /# p value 2 85 %:G- & )F6 ,"Q 132 100 40 +* +* 0*1 0*1 80 35 30 60 S A V 25 40 20 20 2 2 ." ' o/ @ 0 0 Z)& 1 C 1 j& :1 3 R 1 c^d 5 e +, * $ '* [ E 4 6 #, 7 ~$0 o3 * BBm 0 EE@ 9 0 ;a& * * - " # * c #, 8$ ` @ Z * ($ !& 8G ! .[32] ($ C " 6 ' .[24] D C e 47 $ 0 ' " ,0 5^ "/* VAS 0 0 , 1 j& /! )/ @ y 8$ "0 Z ` @ " p R* , C, ? 0 " \d * <9 / . D ' c : - g& % 0 g 5 . " C (mF 6 #, 7 ;a& )/ @ 1 BBm& 0 1 G H * {0 'G7 ` ! ": - "* a& L R=, ($ R - 6 & Downloaded from militarymedj.ir at 7:48 +0330 on Monday September 27th 2021 [33] ? C 1 G H (# G H $ G .[25-27] 12Em ) $ (6! He " G H $ #*0, - (# v$ % 6 #, 7 t R0 B .[34] R - 1 G H $ ? !& 5 e ;a& 6 ' 0 [27] '* [ E : - /* 3 z H R0 B sE 0V * & ( 6 . , ? ,0 $ ? #*0, .[29 28] ($ A#* 0 #*0, "0 0 ? \ B& ; !& ?@ ; $ G H /F [, ( 6 A#* $ c #*0, ? * c ,0 $ ) $ +, * 0 ,0 $ ! R0 B .[30] 6 7 ! 5G ,>0 $&* * < 3 G . C "0 0 "0 # \ B& ?@ ; #*0, G H ;a& 0 6'7+% & g 5 VAS 0 +, * $ ? 0 A#* DNA 8 @& =, .[35] ;p o/ @ 80% * [ E #*0, * ,0 ' .( ,0 U (0 B - i & $ )G$ ? 1 G H * G ^ , ? 6 .[36] 65% 0d .[31] ' B * 2 85 133 … !"# $% & !'(') *!'+ $&,"- .&% / 01 )2% %(" / '3 % ,O & ):0 R - * " e < * $ 0 / " e7 ` ! 0 $ , 0 % "/* ($ R2 . "C$ A$ F 1 # 0 " , +,0{% {0 (L) ... B % R/ C? " ,- S T 1- Woodruff PW, Higgins EM, Vivier AW, Wessely 12- Rice P .Sulphur mustard injuries of the skin. S. Psychiatric illness in patients referred to a der- Pathophysiology and management. Toxicol Rev matology-psychiatry clinic. Gen Hosp Psychiatry, 2003; 22:111-8. 1997; 19:29-35. 13- Herman SM. et al. Antihistamines in the treat- 2- Weldon DR.Quality of life in patients with urti- ment of Atopic Dermatitis. J. Cutan Med Surg caria. Allergy Asthma Proc, 2006; 27:96-9. 2003; Nov. 12-15. 3- Holm EA, Wulf HC, Stegmann H, Jemec GB. Life 14- Malgorzata K. et al. Pruritus in advanced internal quality assessment among patients with atopic ec- diseases, pathogenesis & treatment. The Nether- zema. Br J Dermatol, 2006: 154:719-25. lands J of Med 2001; 28: 27-40. 4- Duque MI, Yosipovitch G, Chan YH, Smith R, 15- Simon FER. et al. The pharmacology and use of Levy P. Itch, pain, and burning sensation.